Skip to content
OpenCapital
Get started

Lantheus Holdings LNTH Reportable — Research And Development Expense

Similar metrics at other companies

Vaxcyte, Inc. logo
PCVXReportable Segment — R&D
$256.43M+147%
Silicon Laboratories logo
SLABReportable Segment — R&D
$88.59M+0.4%
Nextpower Inc. logo
NXTReportable Segment — R&D
$43.17M+83.0%
Regeneron Pharmaceuticals logo
REGNReportable Segment — R&D
$1.54B+16.3%
Apogee Therapeutics, Inc. logo
APGEReportable Segment Aggregation Before Other Operating — Research And Development Expense
$19.54M+34.1%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — R&D
$57.09M+21.8%

Other financials

Income statement

See full
Revenue$377.3M+1.2%
Gross profit$230.9M-2.9%
Operating income$81.3M-20.3%
Net income$118.4M+62.3%
EPS (diluted)$1.80+76.5%

Balance sheet

See full
Cash & equivalents$500.3M-46.8%
Total debt$627.9M+1.8%
Total equity$1.2B+4.1%
Total assets$2.3B+14.2%

Cash flow

See full
Operating cash flow$125.1M+16.3%
CapEx$3.2M-63.0%
Free cash flow$121.9M+23.3%

Valuation

See full
Market cap$6.76B-26.3%
Enterprise value$6.89B-20.5%
P/E24.2×-10.2×
P/S4.4×-1.6×

Profitability

See full
Gross margin60.5%-3.6pp
Operating margin18.8%-10.7pp
Net margin18%+0.7pp
FCF margin24.4%-6.4pp

Returns & leverage

See full
Return on equity23.5%-1.7pp
Debt / equity0.5×0.0×
Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Lantheus Holdings’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's reportable — research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lantheus Holdings's reportable — research and development expense?
Lantheus Holdings (LNTH) reported reportable — research and development expense of $39.38M in Q1 2026.
How has Lantheus Holdings's reportable — research and development expense changed year-over-year?
Lantheus Holdings's reportable — research and development expense increased by 8.4% year-over-year, from $36.31M to $39.38M.
What is the long-term trend for Lantheus Holdings's reportable — research and development expense?
Over 3 years (2022 to 2025), Lantheus Holdings's reportable — research and development expense has grown at a -17.1% compound annual growth rate (CAGR), from $311.68M to $177.31M.
What does reportable — research and development expense mean?
This metric represents the total aggregate expenditure dedicated to research and development activities within the reportable business segment. It reflects the company's overall financial commitment to discovering, developing, and refining diagnostic and therapeutic products to maintain market competitiveness. Analyzing this total spend relative to revenue growth helps investors evaluate the effectiveness of the company's innovation strategy and long-term value creation.